Fluvastatin sodium
Based on 20 publication(s) in Google Scholar
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 93957-55-2
- Formule: C24H25FNNaO4
- Masse moléculaire:433.45
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fluvastatin sodium
More- Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
- Chem Eng J. 1 January 2023, 138972.
- Pharmacol Res. 2023 Apr:190:106724. [Abstract]
- Phytother Res. 2025 May;39(5):1930-1945. [Abstract]
- Cell Prolif. 2021 Jan;54(1):e12953. [Abstract]
- PLoS Biol.2024 May 28;22(5):e3002621. [Abstract]
- Front Bioeng Biotechnol. 2022 Mar 17;10:826093. [Abstract]
- Front Cell Dev Biol. 2020 May 28:8:404. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Mol Med Rep. 2018 Mar;17(3):3944-3950. [Abstract]
- FASEB J. 2026 May 15;40(9):e71873. [Abstract]
- Proteomics. 2023 Aug;23(16):e2300041. [Abstract]
- Pathogens. 2021 Mar 2;10(3):283. [Abstract]
- Front Oncol. 2021 May 10:11:595285. [Abstract]
- FEBS Open Bio. 2025 Aug 8. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- SSRN. 2025 Dec 2.
- SSRN. 2025 Jul 7.
- bioRxiv. 2024 October 04.
- Biomed Pharmacother. 2024 Jun:175:116644. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
IHC
-
Flow Cytometry
-
RT-PCR
-
Cell Proliferation/Viability Assay
Activité biologique
Description
IC50 & Target
IC50: 8 nM (HMG-CoA reductase)[1]
In Vitro
Fluvastatin sodium (XU 62320) is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin (XU 62320), HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin (XU 62320) is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 93957-55-2
-
Appearance Solid
-
Masse moléculaire 433.45
-
Formule C24H25FNNaO4
-
Color Light yellow to yellow
-
SMILES
O=C(O[Na])C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3
-
Synonyms
XU 62-320
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]2024 Jun 18;5(6):101592. PMID: 38843841
Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
HFD C57BL/6 mice intravenously injected with 1 × 106 Cd36NC or Cd36KO C1498 cells were treated with or without reagents (fluvastatin, 40 mg/kg, 5 times/week, intragastric).
Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
Tumors from 3 recipients were dissected for immunohistochemistry staining with anti-human CD3 antibody treated with fluvastatin (40 mg/kg, 5 times/week, i.g.) for 2 weeks.
Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
NOG mice intravenously implanted with 5 × 106 BMMCs from patients with AML were treated with or without fluvastatin (40 mg/kg, 5 times/week, i.g.) for 2 weeks starting 7 days after implantation. 3 days after the last treatment, percentages of human AML cells and human T cells in BM were tested.
-
-
Pharmacol Res
Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs. [Abstract]2023 Apr:190:106724. PMID: 36907287 -
Phytother Res
Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B-Cell Lymphoma Growth by Inhibiting PI3Kα/β and PLK1 Signaling. [Abstract]2025 May;39(5):1930-1945. PMID: 39949030 -
Cell Prolif
Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]2021 Jan;54(1):e12953. PMID: 33211371 -
PLoS Biol
FOXA3 regulates cholesterol metabolism to compensate for low uptake during the progression of lung adenocarcinoma. [Abstract]2024 May 28;22(5):e3002621. PMID: 38805565
Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: PLoS Biol.2024 May 28;22(5):e3002621. [Abstract]
The 7-DHC, cholesterol levels, and qRT-PCR analyses of metastatic-related genes of A549 cells cultured in LPDS medium treated with 5 μg/mL cholesterol with or without 10 μM fluvastatin for 24 h.
Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: PLoS Biol.2024 May 28;22(5):e3002621. [Abstract]
Cell viability of foxa3hi PDO treated with 10 μM Magnolol, 10 μM Fluvastatin, or 10 μM Cisplatin by ATP assay.
-
Front Bioeng Biotechnol
Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]2022 Mar 17;10:826093. PMID: 35372314 -
Front Cell Dev Biol
Construction of Escherichia coli Whole-Cell Biosensors for Statin Efficacy and Production Test. [Abstract]2020 May 28:8:404. PMID: 32671060 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Mol Med Rep
Protection against monocrotaline-induced pulmonary arterial hypertension and caveolin-1 downregulation by fluvastatin in rats. [Abstract]2018 Mar;17(3):3944-3950. PMID: 29286128 -
FASEB J
Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]2026 May 15;40(9):e71873. PMID: 42087353 -
Proteomics
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]2023 Aug;23(16):e2300041. PMID: 37140101 -
Pathogens
Proteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections. [Abstract]2021 Mar 2;10(3):283. PMID: 33801554 -
Front Oncol
Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. [Abstract]2021 May 10:11:595285. PMID: 34041015 -
FEBS Open Bio
Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]2025 Aug 8. PMID: 40781787 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
-
-
-
Biomed Pharmacother
Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs. [Abstract]2024 Jun:175:116644. PMID: 38692057
Solvant et solubilité
In Vitro:
H2O : 50 mg/mL (115.35 mM; Need ultrasonic)
DMSO : 50 mg/mL (115.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Makabe S, et al. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis. 2010 Dec;213(2):377-84. [Content Brief]
[2]. Wu Zhang, et al. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010 Dec;48(12):1167-74. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.3071 mL | 11.5354 mL | 23.0707 mL | 57.6768 mL |
| 5 mM | 0.4614 mL | 2.3071 mL | 4.6141 mL | 11.5354 mL | |
| 10 mM | 0.2307 mL | 1.1535 mL | 2.3071 mL | 5.7677 mL | |
| 15 mM | 0.1538 mL | 0.7690 mL | 1.5380 mL | 3.8451 mL | |
| 20 mM | 0.1154 mL | 0.5768 mL | 1.1535 mL | 2.8838 mL | |
| 25 mM | 0.0923 mL | 0.4614 mL | 0.9228 mL | 2.3071 mL | |
| 30 mM | 0.0769 mL | 0.3845 mL | 0.7690 mL | 1.9226 mL | |
| 40 mM | 0.0577 mL | 0.2884 mL | 0.5768 mL | 1.4419 mL | |
| 50 mM | 0.0461 mL | 0.2307 mL | 0.4614 mL | 1.1535 mL | |
| 60 mM | 0.0385 mL | 0.1923 mL | 0.3845 mL | 0.9613 mL | |
| 80 mM | 0.0288 mL | 0.1442 mL | 0.2884 mL | 0.7210 mL | |
| 100 mM | 0.0231 mL | 0.1154 mL | 0.2307 mL | 0.5768 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Fluvastatin sodium Related Classifications
HY-14664A Related Classifications
Powered by Bioz